Facilitating access to direct-acting antivirals in a community-based point-of-diagnosis model for hepatitis C treatment: The role of the pharmacy team in the no one waits (NOW) study
A sustained partnership with a specialty pharmacy team was critical in transitioning participants to insurance-covered treatment quickly and overcoming barriers, while the study-provided 2-week starter pack facilitated same-day treatment at the point of diagnosis.
Authors
- Claire McDonell (ORCID: https://orcid.org/0009-0005-7116-3346)
- Jeff McKinney
- Jennifer C. Price (ORCID: https://orcid.org/0000-0002-3825-5696)
- Mackenzie Clark
- Meghan D. Morris (ORCID: https://orcid.org/0000-0003-2762-2953)
- Jennifer Nguyen (ORCID: https://orcid.org/0000-0001-8590-8277)
- Annie F. Luetkemeyer (ORCID: https://orcid.org/0000-0003-0911-1578)
- Colleen A McGourty
- Diana Ung
Institutions
- University of California, San Francisco (US)
- Universidad Católica de Santa Fe (AR)
- Universidad Cristiana Autónoma de Nicaragua (NI)
Publication Details
- Journal
- International Journal of Drug Policy
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1016/j.drugpo.2025.104768
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences